000179375 001__ 179375
000179375 005__ 20240229145541.0
000179375 0247_ $$2doi$$a10.1002/ijc.34009
000179375 0247_ $$2pmid$$apmid:35366005
000179375 0247_ $$2ISSN$$a0020-7136
000179375 0247_ $$2ISSN$$a1097-0215
000179375 0247_ $$2altmetric$$aaltmetric:125849364
000179375 037__ $$aDKFZ-2022-00626
000179375 041__ $$aEnglish
000179375 082__ $$a610
000179375 1001_ $$00000-0003-4231-5740$$aClasen, Joanna L$$b0
000179375 245__ $$aBiomarkers of the transsulfuration pathway and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.
000179375 260__ $$aBognor Regis$$bWiley-Liss$$c2022
000179375 3367_ $$2DRIVER$$aarticle
000179375 3367_ $$2DataCite$$aOutput Types/Journal article
000179375 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1657617671_24399
000179375 3367_ $$2BibTeX$$aARTICLE
000179375 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000179375 3367_ $$00$$2EndNote$$aJournal Article
000179375 500__ $$a2022 Sep 1;151(5):708-716
000179375 520__ $$aPrevious studies have suggested that components of one-carbon metabolism, particularly circulating vitamin B6, have an etiological role in renal cell carcinoma (RCC). Vitamin B6 is a cofactor in the transsulfuration pathway. We sought to holistically investigate the role of the transsulfuration pathway in RCC risk. We conducted a nested case-control study (455 RCC cases and 455 matched controls) within the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Plasma samples from the baseline visit were analyzed for metabolites of the transsulfuration pathway, including pyridoxal 5'-phosphate (PLP, the biologically active form of vitamin B6), homocysteine, serine, cystathionine, and cysteine, in addition to folate. Bayesian conditional logistic regression was used to estimate associations of metabolites with RCC risk as well as interactions with established RCC risk factors. Circulating PLP and cysteine were inversely associated with RCC risk, and these association were not attenuated after adjustment for other transsulfuration metabolites (odds ratio (OR) and 90% credible interval (CrI) per 1 SD increase in log concentration: 0.76 [0.66, 0.87]; 0.81 [0.66, 0.96], respectively). A comparison of joint metabolite profiles suggested substantially greater RCC risk for the profile representative of low overall transsulfuration function compared with high function (OR 2.70 [90% CrI 1.26, 5.70]). We found some statistical evidence of interactions of cysteine with body mass index, and PLP and homocysteine with smoking status, on their associations with RCC risk. In conclusion, we found evidence suggesting that the transsulfuration pathway may play a role in metabolic dysregulation leading to RCC development. This article is protected by copyright. All rights reserved.
000179375 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000179375 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000179375 650_7 $$2Other$$adietary biomarkers
000179375 650_7 $$2Other$$akidney cancer
000179375 650_7 $$2Other$$atranssulfuration
000179375 650_7 $$2Other$$avitamin B6
000179375 7001_ $$00000-0001-6517-1300$$aHeath, Alicia K$$b1
000179375 7001_ $$00000-0002-8033-7206$$aVan Puyvelde, Heleen$$b2
000179375 7001_ $$aHuybrechts, Inge$$b3
000179375 7001_ $$00000-0003-2491-5099$$aPark, Jin Young$$b4
000179375 7001_ $$00000-0001-9358-7338$$aFerrari, Pietro$$b5
000179375 7001_ $$aScelo, Ghislaine$$b6
000179375 7001_ $$aUlvik, Arve$$b7
000179375 7001_ $$aMidttun, Øivind$$b8
000179375 7001_ $$aUeland, Per Magne$$b9
000179375 7001_ $$aOvervad, Kim$$b10
000179375 7001_ $$aEriksen, Anne Kirstine$$b11
000179375 7001_ $$aTjønneland, Anne$$b12
000179375 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b13$$udkfz
000179375 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b14$$udkfz
000179375 7001_ $$aSchulze, Matthias B$$b15
000179375 7001_ $$00000-0002-5558-2437$$aPalli, Domenico$$b16
000179375 7001_ $$aAgnoli, Claudia$$b17
000179375 7001_ $$aChiodini, Paolo$$b18
000179375 7001_ $$aTumino, Rosario$$b19
000179375 7001_ $$00000-0002-8008-5096$$aSacerdote, Carlotta$$b20
000179375 7001_ $$00000-0002-6236-6804$$aZamora-Ros, Raul$$b21
000179375 7001_ $$aRodriguez-Barranco, Miguel$$b22
000179375 7001_ $$aSantiuste, Carmen$$b23
000179375 7001_ $$aArdanaz, Eva$$b24
000179375 7001_ $$aAmiano, Pilar$$b25
000179375 7001_ $$aSchmidt, Julie A$$b26
000179375 7001_ $$00000-0003-2237-0128$$aWeiderpass, Elisabete$$b27
000179375 7001_ $$aGunter, Marc$$b28
000179375 7001_ $$aRiboli, Elio$$b29
000179375 7001_ $$aCross, Amanda J$$b30
000179375 7001_ $$aJohansson, Mattias$$b31
000179375 7001_ $$aMuller, David C$$b32
000179375 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.34009$$gp. ijc.34009$$n5$$p708-716$$tInternational journal of cancer$$v151$$x0020-7136$$y2022
000179375 909CO $$ooai:inrepo02.dkfz.de:179375$$pVDB
000179375 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000179375 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000179375 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000179375 9141_ $$y2022
000179375 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-02-04$$wger
000179375 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000179375 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000179375 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000179375 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-25$$wger
000179375 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-25
000179375 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-25
000179375 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-25
000179375 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-25
000179375 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-25
000179375 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-25
000179375 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2021$$d2022-11-25
000179375 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2021$$d2022-11-25
000179375 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000179375 980__ $$ajournal
000179375 980__ $$aVDB
000179375 980__ $$aI:(DE-He78)C020-20160331
000179375 980__ $$aUNRESTRICTED